PROCAIN
-
| StockNo |
Product description |
| EB0280-418-12 |
PROCAIN
AMPOULE 40 MG/2 ML (2%) |
| EB0280-418-33 |
PROCAIN
AMPOULE 100 MG/5 ML (2%) |
| EB0280-418-34 |
PROCAIN
AMPOULE 25 MG/2 ML (0.5%) |
| EB0280-418-35 |
PROCAIN
AMPOULE 50 MG/10 ML (0.5%) |
| EB0280-418-36 |
PROCAIN
AMPOULE 100 MG/5 ML (1%) |
-
- COMPOSITION:
Procaine hydrochloride 40 mg/2 ml; 25 mg/5 ml; 100 mg/5 ml; 50
mg/10 ml and 100 mg/10 ml in one ampoule
ACTION:
Procaine has a well manifested local anesthetic effect, weaker than
that of cocaine and dicaine, but far less toxic. The duration of its
action is about 1 h. it penetrates through the mucus membrane with
difficulty and does not induce vascular spasm. After absorption, it
manifests a short analgesic, antiphlogistic, anti-shock and
anti-arrhythmic effect.
PHARMACOKINETICS:
In the body, it is quickly hydrolyzed to para-aminobenzoic acid and
diethylaminoethanol, which possesses vasodilatory and CNS-excitatory
properties. It is excreted with the urine, about 2 % unchanged and
as metabolites in free or conjugated form.
INDICATIONS:
For infiltration, conduction and spinal anesthesia, as well as for
paranephral, Para vertebral and vagosympathetic blocking, it is used
in gastritis, ulcer disease, acute pancreatitis, some form of
hypertonic disease, cardiac arrhythmias, toxicoses of pregnancy with
hypertension, neurodermitis and during pre- and postoperative
period. In geriatrics it is used for the treatment and prophylaxis
of senile asthenia.
CONTRAINDICATIONS:
Enhanced sensitivity to the drug, myasthenia, hypotension, treatment
with sulfonamides and purulent processes at the site of the
introduction. It should be applied cautiously in cases of grave
hepatic, cardiac and renal insufficiency. |
SIDE EFFECTS:
In enhanced sensitivity to procaine, a general weakness can be
observed as well as dizziness, tinnitus, arterial hypotension,
allergic rashes and anaphylactic shock.
PRECAUTIONS:
The patient should be tested for enhanced sensitivity by
epicutaneous and other tests prior to the application of procain.
DRUG INTERACTIONS:
Epinephrine reduces the toxicity and prolongs the procain effect,
the latter decreasing by the simultaneous admnistration with
glucose, analeptics and calcium drugs. In a combination with
salicylates and sulfonamides, both their bacteriostatic and
anesthetic action are reduced. Procain diminishes the effect of
diuretics.
DOSAGE AND ADMINISTRATION:
For infiltration anesthesia - 0.5 % procain solution together with
epinephrine in a comcentration of up to 0.5 % and for conduction
anesthesia - 1-2 % solutions. For paranephral blocking - 50-80 ml of
0.5 & solution is introduced.
For the treatment of painful syndromes of the digestive tract,
toxicoses of pregnancy, hypertension, vascular spasms, shock, etc.
Procain is applied parenterally (intramuscularly or intravenously -
5 ml of 2 % solution).
In ulcer disease and gastritis it is administered orally - 2-3 times
daily in a dose of 30-50 ml of 0.5 % solution.
MEDICINAL FORM AND PACKAGE:
Packages with 10 and 50 ampoules of
40 mg/2 ml and 100 mg/5 ml (2 %),
25 mg/2 ml and 50 mg/10 ml (0.5 %),
100 mg/5 ml (1 %).
STORAGE:
At moderate temperature (15-30° C), in a place protected from
light.
EXPIRY:
5 (five) years.
|
